Andy Scharenberg is Chief Scientific Officer at Casebia. Before joining Casebia, Scharenberg was an attending physician at Seattle Children’s Hospital and Principal Investigator in the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. In addition, he served as Co-Director of the Program for Cell and Gene Therapy at Seattle Children’s Hospital, a professor in the Department of Pediatrics and adjunct professor in the Department of Immunology at the University of Washington School of Medicine, and a member of the Transplantation Biology Consortium Program at Fred Hutchinson Cancer Research Center. As Chief Scientific Officer at Cellectis, Scharenberg helped implement a gene-editing partnership with Pfizer. He earned his Bachelor of Science in biochemistry from Indiana University and his medical degree from the University of North Carolina School of Medicine.